StockTipsArenaBeta

BUY Lupin Limited — Rajesh Palviya, Axis Securities

BUYLupin Limited
Lupin share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))6 May 2026via CNBC Awaaz.

Entry₹2,442.9Inferred
Target₹2,520
Total upside +3.16% (call closed)
Stop lossNot given
At expiry₹2,285.419 May 2026, 3:30 pm
Expired-6.45%
Follow Rajesh Palviya for new calls(27% target hit, 178 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 1 active Swing call on LUPINSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:33 pm IST
8 supporting1 neutral0 opposing
Supports the BUY call (8)

Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India

NewsGoogle News·19 May · today

(opens in new tab)

Lupin Limited has made its debut in the Dow Jones Best-in-Class Indices 2026, indicating strong performance and adherence to sustainability standards.

NSE · Press Release·19 May · today

(opens in new tab)

Lupin Ltd has received tentative approval from the U.S. FDA for its Revefenacin Inhalation Solution.

BSE · Company Update·18 May · today

(opens in new tab)

Lupin Limited inaugurated Atharv Ability, an advanced multidisciplinary neuro-rehabilitation center in Delhi.

NSE · Press Release·15 May · 4d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Famotidine Injection, USP.

BSE · Company Update·13 May · 5d ago

(opens in new tab)
Neutral / worth noting (1)

The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....

BSE · Board Meeting·7 May · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Rajesh Palviya, Axis Securities

Every call and its outcome